Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

354
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
354
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

1.1K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
1.1K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

419
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
419
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

436
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
436
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

425
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
425
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

578
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
578

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The imaginary divide between mental and "physical" health: Dismantling dualism and reductionism to address a monumental mistake in medicine.

JCPP advances·2026
Same author

Long-Term Opioid Therapy Tapering and Risk of Substance Use Disorder and Overdose: Differences by Opioid Dose and Duration.

Journal of general internal medicine·2026
Same author

Association of Polytrauma Care and Primary Care With Utilization of Health Services for Veterans With Traumatic Brain Injury.

Archives of physical medicine and rehabilitation·2026
Same author

Preponderance of 9-Item Patient Health Questionnaire (PHQ-9) Evidence.

JAMA psychiatry·2026
Same author

Development and field testing of new tools to monitor and evaluate harms of continuing and discontinuing long-term opioid therapy.

Pain·2026
Same author

Psychiatric comorbidity in functional tics: a scoping review.

BMC psychiatry·2026

Related Experiment Video

Updated: Aug 23, 2025

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test
07:54

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test

Published on: June 29, 2018

13.7K

Walking the Benzodiazepine High Wire.

Kurt Kroenke1, Matthew E Hirschtritt1

  • 1Department of Medicine, Indiana University School of Medicine, Indianapolis (Kroenke); Regenstrief Institute, Indianapolis (Kroenke); Division of Research and Department of Psychiatry, Kaiser Permanente Northern California, Oakland (Hirschtritt); Department of Psychiatry and Behavioral Sciences, University of California, San Francisco (Hirschtritt).

Psychiatric Services (Washington, D.C.)
|November 2, 2022
PubMed
Summary
This summary is machine-generated.

Benzodiazepine (BZD) prescriptions have risen, increasing misuse and overdose. While not first-line for chronic anxiety, BZDs effectively treat acute anxiety, with education and surveillance aiding safer prescribing.

Keywords:
Antianxiety agentAnxiety and anxiety disordersBenzodiazepinesEfficacyRisk

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.2K

Related Experiment Videos

Last Updated: Aug 23, 2025

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test
07:54

Testing Animal Anxiety in Rats: Effects of Open Arm Ledges and Closed Arm Wall Transparency in Elevated Plus Maze Test

Published on: June 29, 2018

13.7K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.7K
Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 18, 2008

14.2K

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Public Health

Background:

  • Benzodiazepine (BZD) prescriptions have significantly increased in the last decade.
  • This rise correlates with increased rates of BZD misuse and overdose.
  • Regulatory bodies like the FDA have updated warnings, and guidelines are being re-evaluated.

Purpose of the Study:

  • To examine the current role of benzodiazepines in anxiety treatment.
  • To discuss the implications of increased BZD prescribing.
  • To evaluate strategies for guiding BZD use.

Main Methods:

  • Review of clinical trial evidence on BZD efficacy.
  • Analysis of trends in BZD prescribing.
  • Discussion of regulatory and clinical practice guidelines.

Main Results:

  • Clinical trials confirm the anxiolytic effectiveness of benzodiazepines.
  • Antidepressants and psychotherapy are preferred for chronic anxiety.
  • Benzodiazepines remain valuable for acute, severe, or treatment-resistant anxiety.

Conclusions:

  • Benzodiazepines have a continued role in managing specific anxiety conditions.
  • Provider and patient education, alongside prescribing surveillance, are key.
  • An overly strict regulatory approach may be less effective than guided BZD use.